NanOlogy Revenue and Competitors

Approach: Clinical interest in tumor-directed therapy is increasing because of advancements in interventional oncology and growing recognition of the importance of treating the primary tumor across the disease spectrum. Clinical trials are underway by NanOlogy in multiple therapeutic areas to evaluate tumor-directed drug therapy of concentrated, sustained cancer-killing agents to destroy solid tumors locally without collateral damage to the body and to safely stimulate a favorable immunogenic response to attack metastatic disease. Technology: The NanOlogy proprietary supercritical precipitation (SCP) technology platform precipitates dissolved drug substances with sonication and compressed supercritical carbon dioxide to form stable large surface area microparticles (LSAMs) of pure drug containing no excipients whatsoever. LSAMs have a disproportionately large surface area to particle size ratio that enables entrapment of particles at the disease site and continuous local molecular drug release over time. The initial investigational drugs based on the SCP technology are NanoPac® (LSAM paclitaxel) and NanoDoce® (LSAM docetaxel) clinically demonstrated to release drug at the disease site active against the tumor for weeks while clearing from the body gradually at subtoxic levels. Therapeutic Potential: Therapeutic potential exists for cancer patients across the disease spectrum with NanOlogy tumor-directed investigational drugs. In local disease, the goal is to delay or prevent solid tumor progression as an alternative to organ removal or other invasive procedure as the only curative option. In metastatic disease, the goal is to effect an immunogenic response by sustained primary tumor cell death to boost the local and systemic response to immunoncology therapy without adding to systemic toxicity.